Compare · AKER vs QDEL
AKER vs QDEL
Side-by-side comparison of Akers Biosciences Inc. (AKER) and QuidelOrtho Corporation (QDEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKER and QDEL operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- QDEL carries a market cap of $962.1M.
- QDEL has hit the wire 6 times in the past 4 weeks while AKER has been quiet.
- QDEL has more recent analyst coverage (19 ratings vs 0 for AKER).
- Company
- Akers Biosciences Inc.
- QuidelOrtho Corporation
- Price
- -
- -
- Market cap
- -
- $962.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 19
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Latest AKER
- SEC Form S-3/A filed by Akers Biosciences Inc. (Amendment)
- SEC Form 3: Williams Caroline C claimed ownership of 5,017,423 units of Common Stock
- SEC Form 4 filed by EAGLE CRAIG
- SEC Form 3 filed by EAGLE CRAIG
- Akers Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Kaplin Adam
- SEC Form 3 filed by Kaplin Adam
- SEC Form 4: Schreiber Christopher C exercised 131,750 units of Common Stock at a strike of $0.00 and disposed of $227,798 worth of Common Stock (46,113 units at $4.94), increasing direct ownership by 3,292% to 88,238 units to cover withholding tax
- SEC Form 4 filed by Uzonwanne Jude
- SEC Form 4: Chapman Christopher C JR was granted 96,475 units of Common Stock
Latest QDEL
- QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- QuidelOrtho Reports Third Quarter 2026 Financial Results
- Transforming Data Into Actionable Insights in the Lab
- QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026
- SEC Form 4 filed by QuidelOrtho Corporation
- QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation
- QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
- Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment
- QuidelOrtho Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits